Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 10:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 3,622 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional

Lung Screening Study

NCT00006382
Conditions
Lung Cancer
Interventions
bronchoscopic and lung imaging studies, comparison of screening methods, computed tomography, radiography, study of high risk factors
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Detroit, Michigan + 3 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Osimertinib, Lazertinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
20
States / cities
Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
Conditions
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
ADI-PEG 20, Gemcitabine, Docetaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Fairfax, Virginia
Conditions
Lung Cancer (NSCLC)
Interventions
Cemiplimab, Adjuvant chemotherapy
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Carcinoma
Interventions
Yoga, Support Group Therapy, FACT-L, Pulmonary function test
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Metastatic Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Pemetrexed
Drug · Biological · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
HBI-8000 in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Vinorelbine Tartrate
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
70 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Grand Island, Nebraska • North Platte, Nebraska • Omaha, Nebraska + 1 more
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Conditions
Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gefitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
Interventions
Cisplatin, Carboplatin, Paclitaxel, Vidaza, Tumor Specimen for Methylation Analysis, Blood Sample for Methylation Analysis, Vinorelbine, Docetaxel, Pemetrexed
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Miami, Florida
Conditions
Esophageal Cancer, Lung Cancer
Interventions
Interactive Voice Response System, Symptoms Report
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Interventions
TJ101
Drug
Lead sponsor
Phrontline Biopharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Orlando, Florida • Nashville, Tennessee • Houston, Texas
Conditions
Lung Cancer
Interventions
Dasatinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
9
States / cities
La Jolla, California • New Haven, Connecticut • Boca Raton, Florida + 6 more
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Durvalumab plus SBRT
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Non-Small Cell Lung Cancer
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Interventions
upifitamab rilsodotin
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Paclitaxel 45 mg/m^2, Carboplatin AUC6, Cisplatin 75 mg/m^2, Pemetrexed 500 mg/m^2, Thoracic Radiation Therapy (TRT), Paclitaxel 200 mg/m^2, Carboplatin AUC2
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Santa Rosa, California • Evanston, Illinois • Fort Wayne, Indiana + 7 more
Conditions
Metastatic Cancer, Solid Tumor
Interventions
Sym021, Sym024
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
ALIMTA, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more